J R Maisin1. 1. Université Catholique de Louvain, RBNT/54.69, Brussels, Belgium.
Abstract
PURPOSE: To review and evaluate the development of effective radiation protectors. OUTLINE: Sulphydryl radioprotectors are the best radioprotectors known today. Their use encounters two great difficulties: their toxicity and the short period during which they are active. The biological response modifiers (BRM), developed mainly in the 1990s, demonstrated some protective effects. They can also modulate radiation injury when given after irradiation. In parallel with the use of single radioprotectors, observations have been made in mice using combined treatments with BRM and other radioprotectors. Low-to-moderate doses of several radioprotective agents acting via different mechanisms markedly improved the degree of protection in rodents while maintaining toxicity within acceptable limits, but applications in man remain doubtful. CONCLUSIONS: No radioprotective drug available today has all the requisite qualities to be an ideal radioprotector. Although combinations of radioprotective drugs acting via different mechanisms markedly improve the degree of protection and keep toxicity to acceptable levels in small rodents, attempts to use such treatments in large mammals have been less successful. It is thus questionable whether chemical protection has any prospects for the future.
PURPOSE: To review and evaluate the development of effective radiation protectors. OUTLINE: Sulphydryl radioprotectors are the best radioprotectors known today. Their use encounters two great difficulties: their toxicity and the short period during which they are active. The biological response modifiers (BRM), developed mainly in the 1990s, demonstrated some protective effects. They can also modulate radiation injury when given after irradiation. In parallel with the use of single radioprotectors, observations have been made in mice using combined treatments with BRM and other radioprotectors. Low-to-moderate doses of several radioprotective agents acting via different mechanisms markedly improved the degree of protection in rodents while maintaining toxicity within acceptable limits, but applications in man remain doubtful. CONCLUSIONS: No radioprotective drug available today has all the requisite qualities to be an ideal radioprotector. Although combinations of radioprotective drugs acting via different mechanisms markedly improve the degree of protection and keep toxicity to acceptable levels in small rodents, attempts to use such treatments in large mammals have been less successful. It is thus questionable whether chemical protection has any prospects for the future.
Authors: Dinesh K Thotala; Ling Geng; Amy K Dickey; Dennis E Hallahan; Eugenia M Yazlovitskaya Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-01 Impact factor: 7.038
Authors: Detcho A Stoyanovsky; Zhentai Huang; Jianfei Jiang; Natalia A Belikova; Vladimir Tyurin; Michael W Epperly; Joel S Greenberger; Hülya Bayir; Valerian E Kagan Journal: ACS Med Chem Lett Date: 2011-11-10 Impact factor: 4.345
Authors: Dinesh Thotala; Sergei Chetyrkin; Billy Hudson; Dennis Hallahan; Paul Voziyan; Eugenia Yazlovitskaya Journal: Free Radic Biol Med Date: 2009-06-21 Impact factor: 7.376